Vaxcyte Inc Ordinary Shares PCVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $49.56
- Day Range
- $48.89–50.30
- 52-Week Range
- $29.08–65.00
- Bid/Ask
- $46.00 / $55.00
- Shares Outstanding
- 144.40M
- Market Cap
- $7.12B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 507
- Website
- https://www.vaxcyte.com
Valuation
|
Metric
|
PCVX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.29 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PCVX
|
|---|---|
Quick Ratio | 7.18 |
Current Ratio | 7.49 |
Interest Coverage | — |
Quick Ratio
PCVX
Profitability
|
Metric
|
PCVX
|
|---|---|
Return on Assets (Normalized) | −25.49% |
Return on Equity (Normalized) | −27.83% |
Return on Invested Capital (Normalized) | −30.63% |
Return on Assets
PCVX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Nrtlgsx | Sdhsf | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mdgmpmx | Jjpfprd | $64B | |||
| argenx SE ADR
ARGX
| Hgyfwgj | Kcwwg | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bbkzhgyn | Hxbbr | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Zkgfzjhn | Qhfmvm | $24B | |||
| BioNTech SE ADR
BNTX
| Fznkwvzz | Yrfcm | $23B | |||
| Incyte Corp
INCY
| Kxdpkrjlq | Htvr | $22B | |||
| Moderna Inc
MRNA
| Wcbwlqjt | Gyqvs | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Wdxbqbww | Bpnn | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Gmdmmvh | Pvlp | $13B |
United States